<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01279629</url>
  </required_header>
  <id_info>
    <org_study_id>MED 865-10v3</org_study_id>
    <nct_id>NCT01279629</nct_id>
  </id_info>
  <brief_title>Open Clinical Study, Comparing Non-inferiority of Chronic Plaque Psoriasis</brief_title>
  <acronym>MED</acronym>
  <official_title>Open Clinical Study, Comparing Non-inferiority for Efficacy of the Drug Tazarotene 0.1% Versus the Comparator Drug Calcipotriol 0.005% in the Treatment of Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Farmacêutica Ltda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glenmark Farmacêutica Ltda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

      To evaluate the efficacy of the drugs under study for treating chronic plaque psoriasis.

      - Population:

      50 patients will be selected from both sexes, healthy, between 18 and 65 years with a
      clinical diagnosis of chronic plaque psoriasis with PASI &lt;20%, according to the criteria of
      inclusion and exclusion.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>February 2011</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Tazarotene 0.1%</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcipotriol 0.005%</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).</intervention_name>
    <description>Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.</description>
    <arm_group_label>Tazarotene 0.1%</arm_group_label>
    <arm_group_label>Calcipotriol 0.005%</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        50 patients will be selected from both sexes, healthy, between 18 and 65 years with a
        clinical diagnosis of chronic plaque psoriasis with PASI &lt;20%, according to the criteria of
        inclusion and exclusion.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range: Between 18 and 65

          -  A patient with chronic plaque psoriasis

          -  PASI &lt;20%

          -  Presence of bilateral lesions with at least 2 cm in diameter and each with some degree
             of symmetry

          -  Levels of serum calcium and phosphorus within the normal range of reference or in case
             of changes, classified as irrelevant by the investigator

          -  In the case of female patients, agreement or maintenance of safe use of contraception
             such as barrier (condom, diaphragm), hormonal contraceptives (pills, implants or
             injections), IUDs, or abstinence (no sex)

          -  Reading, understanding, agreement and signature of the patient in the Term of Consent.

        Exclusion Criteria:

          -  Gestation (confirmed by urine test indicator)

          -  Lactation

          -  History of hypersensitivity to components of medicines

          -  Psoriasis with different clinical presentation of the plates

          -  Clinical picture of psoriasis involving only the scalp, face, groin, armpit and / or
             other intertriginous area

          -  Patient requires the use of concomitant medication (topical or systemic) that may
             alter the course of the disease during the study period

          -  Use of any systemic treatment for psoriasis within 12 weeks before the start of the
             study

          -  Use of systemic corticosteroids within 28 days before the start of the study

          -  Use of topical corticosteroids or other topical therapies in the areas of assessment
             within 02 weeks before the start of the study

          -  Use of phototherapy (UVB / UVA-P) within 04 weeks before the start of the study

          -  Patients who have participated in another clinical study within 30 days before the
             start of the study

          -  Use of any medication or possession of any disease which, in the opinion of the
             investigator might interfere with the performance or interpretation of the study

          -  Laboratory tests changed (serum AST and ALT, alkaline phosphatase, urea and
             creatinine, total bilirubin and fractions)

          -  Patients with demonstrated hypercalcemia or evidence of toxicity of vitamin D

          -  Other conditions deemed reasonable by the medical investigator as to the
             disqualification of the individual from study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Schalka</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medcin Instituto da Pele Ltda</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2011</study_first_submitted>
  <study_first_submitted_qc>January 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2011</study_first_posted>
  <last_update_submitted>June 17, 2011</last_update_submitted>
  <last_update_submitted_qc>June 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Glenmark Farmacêutica Ltda</name_title>
    <organization>Glenmark Farmacêutica Ltda</organization>
  </responsible_party>
  <keyword>chronic plaque psoriasis</keyword>
  <keyword>To evaluate the efficacy of the drugs under study for treating chronic plaque psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Tazarotene</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

